| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | pS2; BCEI; HPS2; HP1.A; pNR-2; D21S21 |
| WB Predicted band size | 9 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human TFF1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GRIA3抗体的3篇代表性文献(内容基于模拟生成，非真实文献)：
1. **文献名称**：*GRIA3 Antibody Validation in Neurodevelopmental Disorder Models*
**作者**：Smith A, et al.
**摘要**：本研究通过Western blot和免疫组化验证了一种特异性GRIA3抗体的可靠性，发现其在自闭症模型小鼠前额叶皮质中检测到GRIA3蛋白表达显著降低，支持GRIA3缺失与突触功能异常的关联。
2. **文献名称**：*Subcellular Localization of GRIA3 in Human Neurons Using Immunofluorescence*
**作者**：Chen L, et al.
**摘要**：利用高分辨率免疫荧光技术，作者发现GRIA3抗体标记的蛋白主要富集于神经元树突棘，提示其在突触后信号传递中的关键作用，并证实抗体特异性通过siRNA敲降实验验证。
3. **文献名称**：*GRIA3 Expression Alterations in Schizophrenia: A Post-Mortem Study*
**作者**：Wang X, et al.
**摘要**：通过对比精神分裂症患者与健康人脑组织样本，研究使用GRIA3抗体检测到海马区GRIA3蛋白水平异常上调，可能与谷氨酸能神经传递过度激活有关。
4. **文献名称**：*Comparative Analysis of Commercial GRIA3 Antibodies for Epilepsy Research*
**作者**：Garcia R, et al.
**摘要**：系统评估了4种市售GRIA3抗体的特异性，发现仅两种能在啮齿类动物模型中有效识别目标蛋白，强调了抗体选择对癫痫相关GRIA3突变研究的重要性。
(注：以上文献为示例性质，实际引用请通过PubMed或学术数据库检索真实发表的研究。)
The GRIA3 antibody targets the glutamate ionotropic receptor AMPA type subunit 3 (GluA3), encoded by the GRIA3 gene. This receptor is a critical component of AMPA-type ionotropic glutamate receptors, which mediate fast excitatory synaptic transmission in the central nervous system. GluA3 forms ligand-gated ion channels, typically as heterotetramers with other AMPA receptor subunits (GluA1-4), and plays a role in synaptic plasticity, learning, and memory. Dysregulation of AMPA receptors, including GluA3. has been implicated in neurological disorders such as epilepsy, Alzheimer’s disease, and schizophrenia.
GRIA3 antibodies are widely used in neuroscience research to study receptor expression, localization, and function in both healthy and diseased states. They are employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect GluA3 in brain tissues or cultured neuronal cells. Commercially available GRIA3 antibodies are often raised against specific epitopes, such as the N-terminal extracellular domain or C-terminal regions, and validated for specificity using knockout controls or peptide blocking assays.
Recent studies also explore GRIA3's involvement in cancer, as aberrant glutamate signaling may influence tumor progression. Researchers utilize these antibodies to investigate GluA3's role in cellular pathways, receptor trafficking, and interactions with scaffolding proteins like PSD-95. Variants in GRIA3 have been linked to neurodevelopmental disorders, underscoring its clinical relevance. Proper validation of GRIA3 antibodies remains essential to ensure accurate interpretation in experimental models, from rodents to human post-mortem samples.
×
